Nothing said here yet.
to join the conversation.
| Brumm Joshua TChief Executive Officer | Sell | 7,837 | $131.0K | Fri, Sep 18 |
| McNeill JonathanPresident and COO | Sell | 3,839 | $64.1K | Fri, Sep 18 |
| Brumm Joshua TChief Executive Officer | Sell | 1,610 | $28.8K | Wed, Sep 16 |
| McNeill JonathanPresident and COO | Sell | 731 | $13.1K | Wed, Sep 16 |
| Pinkas JanChief Scientific Officer | Sell | 658 | $11.8K | Wed, Sep 16 |
| Im Ellie EunkyungChief Medical Officer | Sell | 623 | $11.2K | Wed, Sep 16 |
| Bispham Barbara HarlinSee Remarks | Sell | 620 | $11.1K | Wed, Sep 16 |
| Scalzo Richard WilliamChief Financial Officer | Sell | 568 | $10.2K | Wed, Sep 16 |
| Lynch RyanSee Remarks | Sell | 240 | $4.3K | Wed, Sep 16 |
Phase 1/2 APOLLO global clinical trial to evaluate CR-002 in multiple solid tumor types, including non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC), on track to initiate in the fourth quarter of 2026
WALTHAM, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=LwoHWbPj1tvDA4vAOy-m2VP8-12rk8dwDtRbK9xvOVU-xx5hoCkIt2wllfPBY56CwdQel1fYeL-aE4TqW8Zj7pYDtH53FIB5f4PbZyshtno=" rel="nofollow"...
WALTHAM, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma , Inc.
WALTHAM, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc.
Enrollment progressing in ASCEND Phase 1/2 global clinical trial evaluating CR-001, a PD-1 x VEGF bispecific antibody, in multiple solid tumor types in first-line and previously treated patients CR-001 + sacituzumab tirumotecan (sac-TMT) Phase 2 trial in…
WALTHAM, Mass., July 16, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc.
WALTHAM, Mass., July 14, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc.
WALTHAM, Mass., July 14, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc.